MedKoo Cat#: 522560 | Name: Rafabegron

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Rafabegron, also known as AJ-9677; TAK 677; AD 9677, is a potent and selective beta3-adrenoceptor agonist. Rafabegron is a potential treatment of non-insulin dependent diabetes and obesity. Rafabegron has a high relaxant potency on the rat, monkey and human detrusor smooth muscle, and it may have the potential to treat overactive bladder.

Chemical Structure

Rafabegron
Rafabegron
CAS# 244081-42-3

Theoretical Analysis

MedKoo Cat#: 522560

Name: Rafabegron

CAS#: 244081-42-3

Chemical Formula: C21H23ClN2O4

Exact Mass: 402.1346

Molecular Weight: 402.88

Elemental Analysis: C, 62.61; H, 5.75; Cl, 8.80; N, 6.95; O, 15.88

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
TAK 677; TAK-677; TAK677; AD-9677; AD9677; AD 9677; AJ-9677; AJ-9677; AJ-9677; Rafabegron.
IUPAC/Chemical Name
2-((3-((R)-2-(((R)-2-(3-chlorophenyl)-2-hydroxyethyl)amino)propyl)-1H-indol-7-yl)oxy)acetic acid
InChi Key
FHEYFIGWYQJVDR-ACJLOTCBSA-N
InChi Code
InChI=1S/C21H23ClN2O4/c1-13(23-11-18(25)14-4-2-5-16(22)9-14)8-15-10-24-21-17(15)6-3-7-19(21)28-12-20(26)27/h2-7,9-10,13,18,23-25H,8,11-12H2,1H3,(H,26,27)/t13-,18+/m1/s1
SMILES Code
O=C(O)COC1=CC=CC2=C1NC=C2C[C@H](NC[C@@H](C3=CC=CC(Cl)=C3)O)C
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 402.88 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Thiagamoorthy G, Giarenis I, Cardozo L. Early investigational β3 adreno-receptor agonists for the management of the overactive bladder syndrome. Expert Opin Investig Drugs. 2015;24(10):1299-306. doi: 10.1517/13543784.2015.1076390. Epub 2015 Aug 14. PubMed PMID: 26292923. 2: Kullmann FA, Downs TR, Artim DE, Limberg BJ, Shah M, Contract D, de Groat WC, Rosenbaum JS. Urothelial beta-3 adrenergic receptors in the rat bladder. Neurourol Urodyn. 2011 Jan;30(1):144-50. doi: 10.1002/nau.20965. PubMed PMID: 21046653; PubMed Central PMCID: PMC3395322. 3: Fujita M, Ueda T, Iwata M. Stabilization by meglumine of an amine compound degraded by formaldehyde in tablets. Int J Pharm. 2010 Feb 15;386(1-2):195-200. doi: 10.1016/j.ijpharm.2009.11.017. Epub 2009 Dec 2. PubMed PMID: 19931605. 4: Kullmann FA, Limberg BJ, Artim DE, Shah M, Downs TR, Contract D, Wos J, Rosenbaum JS, de Groat WC. Effects of beta3-adrenergic receptor activation on rat urinary bladder hyperactivity induced by ovariectomy. J Pharmacol Exp Ther. 2009 Sep;330(3):704-17. doi: 10.1124/jpet.109.155010. Epub 2009 Jun 10. PubMed PMID: 19515967; PubMed Central PMCID: PMC2729793. 5: Otsuka A, Shinbo H, Hasebe K, Matsumoto R, Ozono S. Effects of a novel beta(3)-adrenoceptor agonist, AJ-9677, on relaxation of the detrusor muscle: an in vitro study. Int J Urol. 2008 Dec;15(12):1072-6. doi: 10.1111/j.1442-2042.2008.02165.x. PubMed PMID: 19120515. 6: Omachi A, Matsushita Y, Kimura K, Saito M. Role of uncoupling protein 1 in the anti-obesity effect of beta3-adrenergic agonist in the dog. Res Vet Sci. 2008 Oct;85(2):214-9. doi: 10.1016/j.rvsc.2007.11.003. Epub 2008 Apr 11. PubMed PMID: 18406437. 7: Omachi A, Ishioka K, Uozumi A, Kamikawa A, Toda C, Kimura K, Saito M. Beta3-adrenoceptor agonist AJ-9677 reduces body fat in obese beagles. Res Vet Sci. 2007 Aug;83(1):5-11. Epub 2006 Nov 30. PubMed PMID: 17140615. 8: Redman LM, de Jonge L, Fang X, Gamlin B, Recker D, Greenway FL, Smith SR, Ravussin E. Lack of an effect of a novel beta3-adrenoceptor agonist, TAK-677, on energy metabolism in obese individuals: a double-blind, placebo-controlled randomized study. J Clin Endocrinol Metab. 2007 Feb;92(2):527-31. Epub 2006 Nov 21. PubMed PMID: 17118998. 9: Sugimoto T, Ogawa W, Kasuga M, Yokoyama Y. Chronic effects of AJ-9677 on energy expenditure and energy source utilization in rats. Eur J Pharmacol. 2005 Sep 5;519(1-2):135-45. PubMed PMID: 16111677. 10: Harada H, Hirokawa Y, Suzuki K, Hiyama Y, Oue M, Kawashima H, Kato H, Yoshida N, Furutani Y, Kato S. Discovery of a novel and potent human and rat beta3-adrenergic receptor agonist, [3-[(2R)-[[(2R)-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-1H-indol-7-yloxy]ac etic acid. Chem Pharm Bull (Tokyo). 2005 Feb;53(2):184-98. PubMed PMID: 15684518. 11: Francke S. TAK-677 (Dainippon/Takeda). Curr Opin Investig Drugs. 2002 Nov;3(11):1624-8. Review. PubMed PMID: 12476963. 12: Sakura H. [Beta 3 adrenergic receptor agonist]. Nihon Rinsho. 2002 Oct;60 Suppl 10:712-8. Review. Japanese. PubMed PMID: 12430307. 13: Noda M. [Tailor-made medicine for diabetes]. Nihon Rinsho. 2002 Jan;60(1):149-53. Review. Japanese. PubMed PMID: 11808326. 14: Sakura H, Togashi M, Iwamoto Y. [beta 3-adrenergic receptor agonists as anti-obese and anti-diabetic drugs]. Nihon Rinsho. 2002 Jan;60(1):123-9. Review. Japanese. PubMed PMID: 11808322. 15: Kato H, Ohue M, Kato K, Nomura A, Toyosawa K, Furutani Y, Kimura S, Kadowaki T. Mechanism of amelioration of insulin resistance by beta3-adrenoceptor agonist AJ-9677 in the KK-Ay/Ta diabetic obese mouse model. Diabetes. 2001 Jan;50(1):113-22. PubMed PMID: 11147775.